Suzanne Fiske
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Suzanne Fiske has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andrew F. Shorr
Washington Hospital Center, Washington, DC 20010, USA
1 shared publication - Brian Harris Nathanson
OptiStatim, LLC , Longmeadow, Massachusetts
1 shared publication - Harlen D Hays
Cerner Corporation, Beverly Hills, CA, USA
1 shared publication - Marya D. Zilberberg
EviMed Research Group, LLC
1 shared publication - Matthew F Emons
Cerner Corporation, Beverly Hills, CA, USA
1 shared publication - Paresh Chaudhari
Astellas Pharma US, Inc, Deerfield, IL, USA
1 shared publication
Latest Publications
- Open Access
- 11 July 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 154
Development and validation of a bedside risk score for MRSA among patients hospitalized with complicated skin and skin structure infections
Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of complicated skin and skin structure infections (cSSSI). Patients with MRSA require different empiric treatment than those with non-MRSA infections, yet no accurate tools exist to aid in stratifying the risk for a MRSA cSSSI. We sought to develop a simple bedside decision rule to tailor empiric coverage more accurately.
- 11 July 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 154
Open AccessDevelopment and validation of a bedside risk score for MRSA among patients hospitalized with complicated skin and skin structure infections
Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of complicated skin and skin structure infections (cSSSI). Patients with MRSA require different empiric treatment than those with non-MRSA infections, yet no accurate tools exist to aid in stratifying the risk for a MRSA cSSSI. We sought to develop a simple bedside decision rule to tailor empiric coverage more accurately.